Skip to content

To evaluate the efficacy and safety of Tianma xiongling Zhixuan tablet in the treatment of primary hypertension with hyperactivity of liver yang or phlegm and blood stasis syndrome, a

To evaluate the efficacy and safety of Tianma xiongling Zhixuan tablet in the treatment of primary hypertension with hyperactivity of liver yang or phlegm and blood stasis syndrome, a

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006606
Enrollment
Unknown
Registered
2022-09-16
Start date
2022-09-16
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Test group: Tianma Xiongling Zhixuan Tablet
TXZTIrbesartan

Sponsors

The First Hospital of Hunan University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Untreated patients who meet the diagnostic criteria of Western medicine for essential hypertension; Or patients with grade 1-2 hypertension who have taken antihypertensive drugs but still have poor blood pressure control; (2) The syndrome differentiation of traditional Chinese medicine is hyperactivity of liver yang or phlegm and blood stasis syndrome; (3) Age 18 ~ 75 years old (including 18 and 75 years old), gender unlimited; (4) Understand and sign the informed consent form; Volunteer subjects and collaborators.

Exclusion criteria

Exclusion criteria: (1) Exclude patients with secondary hypertension and those with grade 3 hypertension; (2) Those who do not meet the TCM syndrome differentiation criteria of hyperactivity of liver yang or phlegm and blood stasis syndrome; (3) Those who are taking traditional Chinese medicine or proprietary Chinese medicine with the effect of calming the liver, resolving phlegm and removing blood stasis (4) Patients who are taking control drugs or angiotensin converting enzyme inhibitors (ACEI) to control blood pressure; (5) 6 people who are taking lithium, potassium preserving diuretics, potassium supplements, potassium containing salt substitutes or other drugs that can increase serum potassium levels (6) Lactating or pregnant women; (7) Patients with serious primary diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system in acute stage or uncontrolled; (8) Allergic constitution, multiple drug allergy or known drug allergy to the test group and the control group; (9) Those who have poor compliance, such as mental diseases, cannot effectively follow the doctor's advice, and thus cannot complete the observation of symptoms and the determination of efficacy and safety during the trial; (10) Those who are participating or have just participated in other clinical trials within 3 months; (11) The researcher judged that it was not suitable to participate in this experiment.

Design outcomes

Primary

MeasureTime frame
(1) Grading and quantitative scoring of TCM related symptoms;Indicators of blood pressure variability: including occasional blood pressure measurement and 24-hour ambulatory blood pressure;

Countries

China

Contacts

Public Contactzhangwen
46890358@qq.com13574891264

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026